for previously treated mCRC regardless of biomarker status, according to the Japanese pharma
Research Dose Ranges Preclinical animal studies: 110 mcg/kg (nanogram to microgram range) once or twice daily Extrapolated human equivalent range commonly discussed in clinical literature: 200500 mcg/day Human pilot IV data: doses up to 20 mg were tolerated without adverse effects in two healthy adults (Lee & Burgess, 2025) though this is far above typical outpatient dosing Protocol: Musculoskeletal / Connective Tissue Healing For tendon, ligament, or muscle injury recovery, the standard approach in clinical functional medicine practice involves: SubQ injection at 200500 mcg once daily , injected near (not into) the injury site Cycle length: typically 48 weeks , with reassessment Often combined with TB-500 (thymosin beta-4) for synergistic tissue remodeling the BPC+TB stack Best results seen alongside physical therapy, not as a substitute for it Protocol: Gut and GI Mucosal Healing For IBD, gut permeability, NSAID damage, or H
The cycles of binding and release can be repeated multiple times, after which the substrate is either released into the cytoplasm to exert its functions or transferred to other chaperone machines, such as Hsp90 (Lang et al., 2021)
If a patient reports side effects, record them in the clinical note with time of onset, severity, and duration
"At the Spa Midtown, we apply Restoracell Serum to the skin before microneedling allowing the serum to sink into the skin by way of the microneedle
